Amicus Therapeutics Inc

Amicus Therapeutics — Q1 2023 Earnings Presentation

24 slides from Amicus Therapeutics's earnings presentation, May 10, 2023

  1. Slide 1: 1Q23 Results Conference Call & Webcast

    AT T H E F O R E F RO N T O F THERAPIES FOR RARE DISEASES 1Q23 Results Conference Call & Webcast May 10, 2023

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and c

  3. Slide 3: A Rare Company

    A Rare Company Patient-dedicated, rare disease biotechnology company with sustained double-digit revenue growth, a global commercial infrastructure, and late-stage development capabilities World-class Gene Therapy Non-GAAP Clinical Platform GLOBAL Development PROFITABILITY COMMERCIAL Leveraging expe

  4. Slide 4: Strategic Priorities

    2023 1 Sustain double-digit Galafold revenue growth of 12-17% at CER1 Strategic Priorities 2 Secure FDA, EMA, and MHRA approvals for AT-GAA 3 Initiate successful global launches of AT-GAA Advance best-in-class, next-generation Fabry and Pompe pipeline 4 programs and capabilities 5 Maintain strong fi

  5. Slide 5: Galafold (migalastat) Continued Growth

    Galafold® (migalastat) Continued Growth Building a leadership position in the treatment of Fabry disease 5

  6. Slide 6: 2023 Galafold Success (as of March 31, 2023)

    2023 Galafold Success (as of March 31, 2023) Building on Galafold’s success and leveraging leadership position to drive continued growth Galafold is the first and only approved oral treatment option with a unique mechanism of action for Fabry patients with amenable variants 86.1M $ 1Q23 Galafold 12-

  7. Slide 7: Galafold Performance

    Galafold Performance Year-over-year reported revenue growth of +10% to $86.1M – Strong operational growth of +14% at CER Year-over-Year Sales Growth +14% -4%  >55% share of treated amenable patients  Global mix of switch (~45%) and previously $86M untreated patients (~55%)1 $79M  Compliance and a

  8. Slide 8: Galafold Quarterly Trends

    Galafold Quarterly Trends Galafold quarterly growth remains strong with Q1 revenue of $86.1M Quarterly Galafold Sales $88M $86M  Expect non-linear quarterly growth to continue due $82M $81M $82M to uneven ordering patterns and FX fluctuations $79M Distribution of Galafold Revenue by Quarter in Past

  9. Slide 9: Galafold Global Commercial Momentum (as of March 31, 2023)

    Galafold Global Commercial Momentum (as of March 31, 2023) Strong patient demand and performance against key metrics lay the foundation for continued double-digit growth in 2023 Sustained Growth in 2023 Driven by: Continued penetration into existing markets Further uptake in diagnosed untreated popu

  10. Slide 10: Pombiliti + Opfolda Launch Preparations

    Pombiliti + Opfolda Launch Preparations Experienced and passionate rare disease commercial and medical organization ready to support second successful product launch Training and launch readiness established across commercial and medical teams Existing relationships with HCPs at key treatment center

  11. Slide 11: AT-GAA

    AT-GAA (cipaglucosidase alfa) + (miglustat) Potential to establish a new standard of care for people living with Pompe disease 11

  12. Slide 12: Pompe Disease Overview

    Pompe Disease Overview Pompe is a severe and fatal neuromuscular disease caused by the deficiency of lysosomal enzyme GAA Majority of patients on current Respiratory and cardiac Estimated incidence of ~1:28,000; Age of onset ranges from standard of care decline after failure are leading causes of Si

  13. Slide 13: AT-GAA: Global Regulatory Status

    AT-GAA: Global Regulatory Status Expect regulatory approvals and launch into the three largest Pompe markets in 2023  Pombiliti® (cipaglucosidase alfa) EC approval granted in March 2023  Opfolda® (miglustat) positive CHMP opinion in April 2023 EC approval expected in 3Q 2023  U.S. FDA pre-approva

  14. Slide 14: AT-GAA: Ongoing Clinical Studies and Expanded Access Mechanisms

    AT-GAA: Ongoing Clinical Studies and Expanded Access Mechanisms Advancing science though ongoing clinical studies and providing expanded access through multiple mechanisms  Ongoing clinical studies in children and adolescents1 with LOPD as well as in Infantile-Onset Pompe Disease (IOPD)  Multiple

  15. Slide 15: Corporate Outlook

    Corporate Outlook Delivering on our mission for patients and shareholders 15

  16. Slide 16: 2023 Select Financial Results

    2023 Select Financial Results 2023 revenue of $86.3M and growth rate of 14% at CER from global sales (in thousands, except per share data) Mar. 31, 2023 Mar. 31, 2022 Product Revenue $86,270 $78,715 Cost of Goods Sold 6,942 7,582 R&D Expense 41,499 81,517 SG&A Expense 73,957 58,116 Changes in Fair V

  17. Slide 17: Financial Outlook and Path to Profitability

    Financial Outlook and Path to Profitability Clear strategy to build our business, advance our portfolio, and achieve profitability Sustain Revenue Secure Approvals Deliver on Growth of AT-GAA Financial Goals $86.3M 1Q 2023 revenue, Focused on prudent +14% YoY expense management Galafold and operatio

  18. Slide 18: Positioned for Significant Value Growth

    Positioned for Significant Value Growth Focused on execution and driving sustainable double-digit revenue growth on path to profitability Continue to Successful Advance Fully leverage Achieve bring Galafold® launch of next-generation global non-GAAP to as many AT-GAA for gene therapies capabilities

  19. Slide 19: Appendix

    Appendix

  20. Slide 20: Reconciliation of Non-GAAP Financial Measures

    Appendix Amicus Therapeutics, Inc. Reconciliation of Non-GAAP Financial Measures (in thousands) Three Months Ended March 31, 2023 2022 Total operating expenses - as reported GAAP $ 116,964 $ 146,472 Research and development: Stock-based compensation 8,490 9,365 Selling, general and administrative: S

  21. Slide 21: 2022 Environmental, Social, & Governance (ESG) Snapshot

    2022 Environmental, Social, & Governance (ESG) Snapshot Who We Serve Environmental Our mission is to Diversity, Equity, & Management drive sustainability with our partners Inclusion (DEI) Address a rare genetic disease by incorporating Programs we Committed to producing Pledge to support a more incl

  22. Slide 22: FX Sensitivity and Galafold Distribution of Quarterly Sales

    FX Sensitivity and Galafold Distribution of Quarterly Sales Impact from Foreign Currency Q1 2023 Currency Variances: Q1 2022 Q1 2023 YoY Variance USD/ EUR 1.122 1.073 (4.4%) Distribution of Galafold Revenue GBP 1.342 1.215 (9.5%) by Quarter in Past 5 years: JPY 0.009 0.008 (12.2%) Q1 Q2 Q3 Q4 5 Year

  23. Slide 23: Amicus Pipeline

    Amicus Pipeline Streamlined rare disease pipeline with focus on Fabry disease and Pompe disease franchises INDICATION D I S C O V E R Y P R E C L I N I C A L P H A S E 1 / 2 P H A S E 3 R E G U L A T O R Y C O M M E R C I A L FAB RY F RANC H IS E Galafold®(migalastat) ODD Fabry Gene Therapy Next-Gen

  24. Slide 24: Thank you

    Thank you

Amicus Therapeutics — Q1 2023 Earnings Presentation on 6ix